HRP20150513T1 - Novi polimorf - Google Patents

Novi polimorf Download PDF

Info

Publication number
HRP20150513T1
HRP20150513T1 HRP20150513TT HRP20150513T HRP20150513T1 HR P20150513 T1 HRP20150513 T1 HR P20150513T1 HR P20150513T T HRP20150513T T HR P20150513TT HR P20150513 T HRP20150513 T HR P20150513T HR P20150513 T1 HRP20150513 T1 HR P20150513T1
Authority
HR
Croatia
Prior art keywords
solid form
form according
nocturia
vasopressin
solvate
Prior art date
Application number
HRP20150513TT
Other languages
English (en)
Croatian (hr)
Inventor
Johan Henrik Kjellström
Björn Erik Johanson
Thomas Vilhelmsen
Original Assignee
Vantia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia Limited filed Critical Vantia Limited
Publication of HRP20150513T1 publication Critical patent/HRP20150513T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
HRP20150513TT 2010-04-01 2011-03-31 Novi polimorf HRP20150513T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1005623.2A GB201005623D0 (en) 2010-04-01 2010-04-01 New polymorph
US34704810P 2010-05-21 2010-05-21
EP11714079.8A EP2552910B1 (en) 2010-04-01 2011-03-31 New polymorph
PCT/GB2011/000500 WO2011121308A1 (en) 2010-04-01 2011-03-31 New polymorph

Publications (1)

Publication Number Publication Date
HRP20150513T1 true HRP20150513T1 (hr) 2015-06-05

Family

ID=42228830

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150513TT HRP20150513T1 (hr) 2010-04-01 2011-03-31 Novi polimorf

Country Status (20)

Country Link
US (1) US9079881B2 (enExample)
EP (1) EP2552910B1 (enExample)
JP (1) JP5802737B2 (enExample)
KR (1) KR101792621B1 (enExample)
CN (1) CN102918038B (enExample)
CA (1) CA2795109C (enExample)
DK (1) DK2552910T3 (enExample)
ES (1) ES2538085T3 (enExample)
GB (1) GB201005623D0 (enExample)
HR (1) HRP20150513T1 (enExample)
HU (1) HUE026442T2 (enExample)
ME (1) ME02102B (enExample)
MX (1) MX2012011382A (enExample)
PL (1) PL2552910T3 (enExample)
PT (1) PT2552910E (enExample)
RS (1) RS53956B1 (enExample)
RU (1) RU2559633C2 (enExample)
SI (1) SI2552910T1 (enExample)
SM (1) SMT201500107B (enExample)
WO (1) WO2011121308A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
CN108026059A (zh) 2015-07-22 2018-05-11 阿纳韦克斯生命科学公司 四氢-n,n-二甲基-2,2-二苯基-3-呋喃甲胺盐酸盐的晶型,制备这样晶型的方法,及其药物组合物
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
BR9811585A (pt) 1997-07-30 2000-09-26 American Home Prod Agonistas de vasopressinas tricìclicas
EP1000059B1 (en) 1997-07-30 2004-09-29 Wyeth Tricyclic vasopressin agonists
CN1347415A (zh) 1999-02-04 2002-05-01 美国家用产品公司 三环吡啶n-氧化物血管升压素激动剂
WO2000046225A2 (en) 1999-02-04 2000-08-10 American Home Products Corporation Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
JP2002536378A (ja) 1999-02-04 2002-10-29 ワイス ピロロベンゾジアゼピンカルボキシアミドバソプレシンアゴニスト
CN1339036A (zh) 1999-02-04 2002-03-06 美国家用产品公司 作为血管加压素激动剂的噻吩基苯甲酰基苯并吖庚因
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents

Also Published As

Publication number Publication date
EP2552910A1 (en) 2013-02-06
US20140296213A1 (en) 2014-10-02
SI2552910T1 (sl) 2015-06-30
SMT201500107B (it) 2015-07-09
KR20130023218A (ko) 2013-03-07
CA2795109C (en) 2018-04-17
CA2795109A1 (en) 2011-10-06
RS53956B1 (sr) 2015-08-31
ME02102B (me) 2015-10-20
RU2012146544A (ru) 2014-05-10
RU2559633C2 (ru) 2015-08-10
KR101792621B1 (ko) 2017-11-02
DK2552910T3 (en) 2015-04-07
US9079881B2 (en) 2015-07-14
WO2011121308A1 (en) 2011-10-06
MX2012011382A (es) 2013-01-29
PL2552910T3 (pl) 2015-07-31
JP2013523706A (ja) 2013-06-17
ES2538085T3 (es) 2015-06-17
PT2552910E (pt) 2015-05-13
CN102918038A (zh) 2013-02-06
EP2552910B1 (en) 2015-03-11
HUE026442T2 (en) 2016-06-28
GB201005623D0 (en) 2010-05-19
CN102918038B (zh) 2015-09-09
JP5802737B2 (ja) 2015-11-04

Similar Documents

Publication Publication Date Title
HRP20150513T1 (hr) Novi polimorf
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
HRP20192132T1 (hr) Antagonist nk-1/nk-3 receptora za liječenje valunga
PL3290414T3 (pl) Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu
JP2014507446A5 (enExample)
NZ603789A (en) Heteroaryl compounds and methods of use thereof
JP2014162794A5 (enExample)
JP2017514910A5 (enExample)
NZ603043A (en) Pharmaceutical compositions comprising cftr modulators and administrations thereof
CL2009001125A1 (es) Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
MX2012012571A (es) Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas.
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
HRP20171151T1 (hr) Inhibitori cdc7
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
WO2012096929A3 (en) Heteroaryl compounds and methods of use thereof
JP2013522326A5 (enExample)
JP2013507408A5 (enExample)
IL185892A0 (en) Novel compounds and their isomers and pharmaceutical compositions containing the same as vanilloid receptor antagonists
NZ605431A (en) D2 antagonists, methods of synthesis and methods of use
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
IN2014DN07885A (enExample)
JP2013515006A5 (enExample)
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib